Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asston PharmaceuticalsBOM:544445 -0.59%19 Gross Margin % is 16.42% as of Mar. 2026, which is 56% below its 10-year median of 37.42. GuruFocus rates BOM:544445 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Asston Pharmaceuticals ranks worse than 78.37% on this metric.
BOM:544445's Gross Margin % is ranked worse than 78.37% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:544445: 31.63
Asston Pharmaceuticals had a gross margin of 16.42% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Asston Pharmaceuticals was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Asston Pharmaceuticals had a gross margin of 16.42% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Asston Pharmaceuticals Gross Margin % Related Terms
Asston Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Asston Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Asston Pharmaceuticals (BOM:544445) has a Gross Margin % of 16.42% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Asston Pharmaceuticals and its competitors. This is 56% below median its historical median of 37.42. Over the past decade, Asston Pharmaceuticals' Gross Margin % has ranged from 20.05 to 48.77. According to the industry distribution chart, Asston Pharmaceuticals ranks #739 out of 943 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Asston Pharmaceuticals' Gross Margin % too high?
Asston Pharmaceuticals' current Gross Margin % of 16.42% is 56% below median its 10-year median of 37.42. Over the past 10 years, this metric has ranged from a low of 20.05 to a high of 48.77. The Drug Manufacturers industry median Gross Margin % is 48.54. Asston Pharmaceuticals' value of 16.42% is 66.2% below this industry median. Based on the distribution chart, Asston Pharmaceuticals ranks #739 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Asston Pharmaceuticals ranks #739 out of 943 companies for Gross Margin %. This places Asston Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. Asston Pharmaceuticals' value of 16.42% is 66.2% below this benchmark. Historically, Asston Pharmaceuticals' own Gross Margin % has ranged from 20.05 to 48.77 over the past decade. While the company's 10-year median is 37.42 vs. the industry median of 48.54, Asston Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asston Pharmaceuticals's current Gross Margin % of 16.42% is 66.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Asston Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asston Pharmaceuticals's current Gross Margin % is 16.42%, which is 56% below median its own 10-year median of 37.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Gross Margin % of 16.42%. The current Gross Margin % is 16.42%, which is 56% below median its 10-year median of 37.42 and 66.2% below the Drug Manufacturers industry median of 48.54. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Gross Margin % is 16.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
